DrugPatentWatch Database Preview

Drugs in Development Information for Rigosertib

Drug Development Status for Rigosertib: Sponsors, patents, clinical trial progress

Rigosertib is an investigational drug.

There have been 27 clinical trials for Rigosertib. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1^st 2013.

The most common disease conditions in clinical trials are Syndrome, Preleukemia, and Myelodysplastic Syndromes. The leading clinical trial sponsors are Onconova Therapeutics, Inc., M.D. Anderson Cancer Center, and Academic Oncology Gastrointestinal Cancer Consortium (AGICC).

There are thirteen US patents protecting this investigational drug and seventy-eight international patents.

Summary for Rigosertib

US Patents	13
International Patents	78
US Patent Applications	20
WIPO Patent Applications	18
Japanese Patent Applications	0
Clinical Trial Progress	Phase 3 (2013-08-01)
Vendors	43

Recent Clinical Trials for Rigosertib

Title	Sponsor	Phase
Rigosertib for RDEB-SCC	Prof. Johann Bauer	Phase 1/Phase 2
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia	Onconova Therapeutics, Inc.	Phase 2
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia	M.D. Anderson Cancer Center	Phase 2

See all Rigosertib clinical trials

Clinical Trial Summary for Rigosertib

Top disease conditions for Rigosertib

Top clinical trial sponsors for Rigosertib

See all Rigosertib clinical trials

US Patents for Rigosertib

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Request a Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Rigosertib	See Pricing	Formulations with enhanced stability and bioavailability for administration of (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones	ONCONOVA THERAPEUTICS, INC. (Newtown, PA)	See Pricing
Rigosertib	See Pricing	Substituted alkyl diaryl derivatives, methods of preparation and uses	TEMPLE UNIVERSITY--Of The Commonwealth System of Higher Education (Philadelphia, PA)	See Pricing
Rigosertib	See Pricing	Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders	Temple University - Of the Commonwealth System of Higher Education (Philadelphia, PA) Onconova Therapeutics, Inc. (Newtown, PA)	See Pricing
Rigosertib	See Pricing	Formulations for parenteral administration of (e)-2, 6-dialkoxystyryl 4-substituted benzylsulfones	Onconova Therapeutics, Inc. (Newtown, PA)	See Pricing
Rigosertib	See Pricing	Composition and methods for the treatment of proliferative diseases	Temple University - Of The Commonwealth System of Higher Education (Philadelphia, PA) Mount Sinai School of Medicine (New York, NY)	See Pricing
Rigosertib	See Pricing	Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis	Temple University--Of The Commonwealth System of Higher Education (Philadelphia, PA) Onconova Therapeutics, Inc. (Newtown, PA)	See Pricing
Rigosertib	See Pricing	Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones	Temple University--Of The Commonwealth System of Higher Education (Philadelphia, PA) Onconova Therapeutics, Inc. (Newtown, PA)	See Pricing
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

International Patents for Rigosertib